Texas House Bill HB4173

Texas 2021 - 87th Regular

Caption

Relating to the prohibited use of a Federal Drug Enforcement Administration number.

Impact

The implications of HB 4173 are significant for pharmacists and other healthcare practitioners, emphasizing the importance of adhering to federal standards. By creating a clear restriction on the misuse of DEA numbers, the bill intends to enhance the integrity of pharmaceutical practices and reduce any potential for fraud or misuse that could compromise the health and safety of patients. The classification of violations as Class C misdemeanors helps ensure compliance by outlining penalties for those who might flout these regulations.

Summary

House Bill 4173 addresses the regulations surrounding the use of Federal Drug Enforcement Administration (DEA) numbers by individuals in Texas, particularly pharmacists. The bill amends Section 481.003 of the Health and Safety Code to explicitly prohibit individuals from using a practitioner’s DEA number for purposes not authorized by federal law or state law. This change aims to tighten the control over how DEA numbers are utilized in prescribing and dispensing controlled substances, thereby promoting safer and more accountable practices within the pharmaceutical field.

Conclusion

Overall, HB 4173 represents an effort to improve the regulatory framework governing the prescribing and dispensing of medications in Texas. By focusing on the responsible use of DEA numbers, the bill aims to protect public health while also addressing practices within the pharmaceutical industry that could lead to misuse and abuse of controlled substances.

Contention

While the bill itself mainly introduces straightforward prohibitions on the misuse of DEA numbers, discussions around it may highlight concerns regarding the existing enforcement of regulations and possible burdens on practitioners. Some stakeholders may argue that stricter regulations could hinder access to necessary medications for patients, particularly in rural or underserved areas where medical professionals may already face challenges in prescribing controlled substances efficiently.